• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Monte Rosa Therapeutics Inc.

    10/3/25 12:19:09 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GLUE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Monte Rosa Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    61225M102

    (CUSIP Number)


    05/16/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    61225M102


    1Names of Reporting Persons

    Adam Goulburn
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    AUSTRALIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,757,563.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,757,563.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,757,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    61225M102


    1Names of Reporting Persons

    Zavain Dar
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,757,563.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,757,563.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,757,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    61225M102


    1Names of Reporting Persons

    Nan Li
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,757,563.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,757,563.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,757,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    61225M102


    1Names of Reporting Persons

    Dimension Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,757,563.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,757,563.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,757,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    61225M102


    1Names of Reporting Persons

    Dimension Capital I GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,757,563.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,757,563.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,757,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    61225M102


    1Names of Reporting Persons

    Dimension Management GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,757,563.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,757,563.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,757,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    61225M102


    1Names of Reporting Persons

    Dimension Capital I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,757,563.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,757,563.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,757,563.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Monte Rosa Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    321 Harrison Avenue, Suite 900, Boston, MA 02118
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Monte Rosa Therapeutics, Inc. (the "Issuer") are: Adam Goulburn Zavain Dar Nan Li Dimension Management, L.P. ("Dimension Management") Dimension Capital I GP, LLC ("Dimension Capital I GP") Dimension Management GP, LLC ("Dimension Management GP") Dimension Capital I, L.P. ("Dimension Capital I")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is 632 Broadway, Suite 801, New York, NY 10012.
    (c)Citizenship:

    Mr. Goulburn is an Australian citizen. Each of Mr. Dar and Mr. Li is a United States citizen. Each of Dimension Management and Dimension Capital is a Delaware limited partnership. Each of Dimension Capital I GP and Dimension Management GP is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    61225M102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 61,759,350 outstanding shares of Common Stock as of August 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025. Dimension Capital I directly holds 4,757,563 shares of Common Stock. Dimension Management is the investment advisor to Dimension Capital I, and Dimension Management GP is the general partner of Dimension Management. Dimension Capital I GP is the general partner to the general partner of Dimension Capital I. Mr. Goulburn, Mr. Dar, and Mr. Li are members of each of Dimension Management GP and Dimension Capital I GP.
    (b)Percent of class:

    The information required by this item with respect to each Reporting Person is set forth in Row 11 of the cover pages to this Schedule 13G.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by this item with respect to each Reporting Person is set forth in Row 5 of the cover pages to this Schedule 13G.

     (ii) Shared power to vote or to direct the vote:

    The information required by this item with respect to each Reporting Person is set forth in Row 6 of the cover pages to this Schedule 13G.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by this item with respect to each Reporting Person is set forth in Row 7 of the cover pages to this Schedule 13G.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by this item with respect to each Reporting Person is set forth in Row 8 of the cover pages to this Schedule 13G.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Adam Goulburn
     
    Signature:/s/ Adam Goulburn
    Name/Title:Adam Goulburn
    Date:10/03/2025
     
    Zavain Dar
     
    Signature:/s/ Zavain Dar
    Name/Title:Zavain Dar
    Date:10/03/2025
     
    Nan Li
     
    Signature:/s/ Nan Li
    Name/Title:Nan Li
    Date:10/03/2025
     
    Dimension Management, L.P.
     
    Signature:/s/ Adam Goulburn
    Name/Title:By: Dimension Management GP, LLC, its general partne; By: Adam Goulburn, Member
    Date:10/03/2025
     
    Dimension Capital I GP, LLC
     
    Signature:/s/ Adam Goulburn
    Name/Title:Adam Goulburn, Member
    Date:10/03/2025
     
    Dimension Management GP, LLC
     
    Signature:/s/ Adam Goulburn
    Name/Title:Adam Goulburn, Member
    Date:10/03/2025
     
    Dimension Capital I, L.P.
     
    Signature:/s/ Adam Goulburn
    Name/Title:By: Dimension Capital I GP, LP, its general partner; By: Adam Goulburn, Member
    Date:10/03/2025
    Exhibit Information

    99.1 Joint Filing Agreement

    Get the next $GLUE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLUE

    DatePrice TargetRatingAnalyst
    12/19/2024$14.00 → $11.00Overweight → Equal Weight
    Wells Fargo
    2/15/2024$11.00Outperform
    Wedbush
    1/3/2023$18.00Equal Weight → Overweight
    Wells Fargo
    10/13/2022$22.00Buy
    UBS
    8/15/2022$20.00Buy
    Jefferies
    4/28/2022$19.00Neutral
    Credit Suisse
    2/10/2022$19.00Equal-Weight
    Wells Fargo
    10/14/2021$20.00Mkt Perform
    SVB Leerink
    More analyst ratings

    $GLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Behbahani Ali

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    6/16/25 4:10:47 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Hughes Eric A

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    6/16/25 4:05:11 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Siu Christine

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    6/16/25 4:05:06 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    3/25/25 6:32:00 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLUE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Monte Rosa Therapeutics Inc.

    SCHEDULE 13G - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

    10/3/25 12:19:09 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

    9/15/25 7:01:06 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.

    SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

    8/14/25 7:10:41 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLUE
    Leadership Updates

    Live Leadership Updates

    View All

    Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

    BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa. "I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Eric brings extensive experience building and lea

    12/13/24 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

    BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. "Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we're delighted to have him on our team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Tony's experience developing multiple first-in-class therapeutics for the treatment of

    7/26/23 7:30:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

    BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Directors, bringing his extensive experience as a life sciences leader to the team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Having served as the CEO of two clinical-stage companies, Jan has demon

    3/23/23 7:30:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

    SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

    11/14/24 1:22:39 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

    SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

    11/12/24 10:32:12 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Monte Rosa Therapeutics Inc.

    SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

    10/30/24 5:10:55 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLUE
    Financials

    Live finance-specific insights

    View All

    Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

    Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; depr

    3/20/25 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

    Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors. A conference call and webcast are planned for 

    3/11/25 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

    Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call and webcast at 8:00 a.m. ET today BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including l

    10/17/23 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

    Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales Extended cash runway enables Monte Rosa to accelerate preclinical and clinical-stage immunology & inflammation (I&I) pipeline BOSTON, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company develop

    9/15/25 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

    BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.Stifel 2025 Virtual Immunology and Inflammation Forum – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 15, 2025, at 9:00 a.m. ET. A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com, and an archiv

    9/2/25 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

    MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026 Additional Phase 1 cohort designed to evaluate potential early proof of concept in subjects with increased cardiovascular disease (CVD) risk and elevated CRP BOSTON, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first subjects have been dosed in a Ph

    7/21/25 7:00:13 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Monte Rosa Therapeutics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Monte Rosa Therapeutics from Overweight to Equal Weight and set a new price target of $11.00 from $14.00 previously

    12/19/24 7:39:47 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Monte Rosa Therapeutics with a new price target

    Wedbush initiated coverage of Monte Rosa Therapeutics with a rating of Outperform and set a new price target of $11.00

    2/15/24 6:27:11 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Monte Rosa Therapeutics from Equal Weight to Overweight and set a new price target of $18.00

    1/3/23 8:03:46 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care